卵巣癌治療薬の世界市場2019-2023

◆英語タイトル:Global Ovarian Cancer Drugs Market 2019-2023
◆商品コード:IRTNTR30795
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年2月23日
◆ページ数:117
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、卵巣癌治療薬の世界市場について調査・分析し、市場概要、市場環境、卵巣癌治療薬市場規模、種類別(上皮性卵巣癌、胚細胞卵巣癌、間質細胞卵巣癌、小細胞卵巣癌)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・卵巣癌治療薬の世界市場概要
・卵巣癌治療薬の世界市場環境
・卵巣癌治療薬の世界市場動向
・卵巣癌治療薬の世界市場規模
・卵巣癌治療薬の世界市場:業界構造分析
・卵巣癌治療薬の世界市場:種類別(上皮性卵巣癌、胚細胞卵巣癌、間質細胞卵巣癌、小細胞卵巣癌)
・卵巣癌治療薬の世界市場:地域別市場規模・分析
・卵巣癌治療薬の北米市場規模・予測
・卵巣癌治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・卵巣癌治療薬のアジア太平洋市場規模・予測
・卵巣癌治療薬の主要国分析
・卵巣癌治療薬の世界市場:意思決定フレームワーク
・卵巣癌治療薬の世界市場:成長要因、課題
・卵巣癌治療薬の世界市場:競争環境
・卵巣癌治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors. In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period. Technavio’s analysts have predicted that the ovarian cancer drugs market will register a CAGR of over 22% by 2023.
Market Overview
Increasing awareness of ovarian cancer
The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.
High cost of treatment
The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.
For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Epithelial ovarian cancer – Market size and forecast 2018-2023
• Germ cell ovarian cancer – Market size and forecast 2018-2023
• Stromal cell ovarian cancer – Market size and forecast 2018-2023
• Small cell ovarian cancer – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Clovis Oncology
• F. Hoffmann-La Roche
• Spectrum Pharmaceuticals
• TESARO
PART 14: APPENDIX
• Research methodology
List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Epithelial ovarian cancer – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Epithelial ovarian cancer – Year-over-year growth 2019-2023 (%)
Exhibit 23: Germ cell ovarian cancer – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Germ cell ovarian cancer – Year-over-year growth 2019-2023 (%)
Exhibit 25: Stromal cell ovarian cancer – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Stromal cell ovarian cancer – Year-over-year growth 2019-2023 (%)
Exhibit 27: Small cell ovarian cancer – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Small cell ovarian cancer – Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America – Year-over-year growth 2019-2023 (%)
Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 37: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Decision framework
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AstraZeneca – Vendor overview
Exhibit 51: AstraZeneca – Product segments
Exhibit 52: AstraZeneca – Organizational developments
Exhibit 53: AstraZeneca – Geographic focus
Exhibit 54: AstraZeneca – Key offerings
Exhibit 55: Clovis Oncology – Vendor overview
Exhibit 56: Clovis Oncology – Product segments
Exhibit 57: Clovis Oncology – Organizational developments
Exhibit 58: Clovis Oncology – Geographic focus
Exhibit 59: Clovis Oncology – Key offerings
Exhibit 60: F. Hoffmann-La Roche – Vendor overview
Exhibit 61: F. Hoffmann-La Roche – Business segments
Exhibit 62: F. Hoffmann-La Roche – Organizational developments
Exhibit 63: F. Hoffmann-La Roche – Geographic focus
Exhibit 64: F. Hoffmann-La Roche – Segment focus
Exhibit 65: F. Hoffmann-La Roche – Key offerings
Exhibit 66: Spectrum Pharmaceuticals – Vendor overview
Exhibit 67: Spectrum Pharmaceuticals – Business segments
Exhibit 68: Spectrum Pharmaceuticals – Organizational developments
Exhibit 69: Spectrum Pharmaceuticals – Geographic focus
Exhibit 70: Spectrum Pharmaceuticals – Key offerings
Exhibit 71: TESARO – Vendor overview
Exhibit 72: TESARO – Business segments
Exhibit 73: TESARO – Organizational developments
Exhibit 74: TESARO – Geographic focus
Exhibit 75: TESARO – Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations



【掲載企業】

AstraZeneca、Clovis Oncology、F. Hoffmann-La Roche、Spectrum Pharmaceuticals、TESARO

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[卵巣癌治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆